Literature DB >> 16908339

The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis.

Vik Khullar1, Christopher Chapple, Zahava Gabriel, Julie Ann Dooley.   

Abstract

The objective of this study was to review the effects of antimuscarinic treatments on health-related quality of life (HRQL) in patients with overactive bladder (OAB). MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and the Cumulative Index to Nursing and Allied Health Literature databases were searched from 1966 through August 2004 for randomized controlled trials of antimuscarinic agents. HRQL data from included trials were extracted, and meta-analysis was performed where possible. Of 56 trials included, 25 (45%) reported HRQL and/or patient-reported outcomes. The most commonly used instruments were the Incontinence Impact Questionnaire (3 trials), the King's Health Questionnaire (KHQ; 5 trials), the Medical Outcomes Study Short Form-36 (2 trials), the Gaudenz Appraisal Questionnaire (3 trials), and the Urogenital Distress Inventory (2 trials). Results from the meta-analyses of placebo-controlled trials showed statistically significant differences in favor of antimuscarinic therapy. Differences in HRQL as assessed using the KHQ were also clinically meaningful. The meta-analysis results of active-controlled trials did not show significant differences among antimuscarinic agents. This review provides evidence that antimuscarinics provide an HRQL benefit to patients with OAB. HRQL outcomes using validated instruments are recommended for inclusion in active-controlled trials, and agreement on the most appropriate HRQL instrument is now required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908339     DOI: 10.1016/j.urology.2006.05.043

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  Validity and reliability of patient selected goals as an outcome measure in overactive bladder.

Authors:  Rufus Cartwright; Sushma Srikrishna; Linda Cardozo; Dudley Robinson
Journal:  Int Urogynecol J       Date:  2011-01-29       Impact factor: 2.894

2.  Functional improvement in spinal cord injury-induced neurogenic bladder by bladder augmentation using bladder acellular matrix graft in the rat.

Authors:  Shinji Urakami; Hiroaki Shiina; Hideki Enokida; Ken Kawamoto; Nobuyuki Kikuno; Thomas Fandel; Kaveh Vejdani; Lora Nunes; Mikio Igawa; Emil A Tanagho; Rajvir Dahiya
Journal:  World J Urol       Date:  2007-01-13       Impact factor: 4.226

Review 3.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

4.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

5.  The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.

Authors:  Suleyman Sami Cakir; Recep Burak Degirmentepe; Hasan Anil Atalay; Halil Lutfi Canat; Sait Ozbir; Mehmet Gokhan Culha; Emre Can Polat; Alper Otunctemur
Journal:  Int Urol Nephrol       Date:  2018-11-17       Impact factor: 2.370

6.  Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats.

Authors:  Takeya Kitta; Vikas Tyagi; Masato Nanri; Mamoru Kiniwa; Katsuya Nonomura; Naoki Yoshimura
Journal:  Int Urogynecol J       Date:  2012-08-29       Impact factor: 2.894

7.  Medical management of overactive bladder.

Authors:  Sarvpreet S Ubee; Ramaswamy Manikandan; Gurpreet Singh
Journal:  Indian J Urol       Date:  2010-04

Review 8.  Considerations for the management of urgency symptoms in patients with overactive bladder syndrome.

Authors:  Linda D Cardozo; Philip E V A Van Kerrebroeck; David R Staskin
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

9.  Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?

Authors:  Aswini Balachandran; Natasha Curtiss; Maya Basu; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2014-07-17       Impact factor: 2.894

10.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.